دورية أكاديمية
أعرض في EDS

The implication of miR-200a and miR-132 expression and their correlations with NF-κB/TNF-alpha signaling in adults with diabetic nephropathy.

التفاصيل البيبلوغرافية
العنوان: The implication of miR-200a and miR-132 expression and their correlations with NF-κB/TNF-alpha signaling in adults with diabetic nephropathy.
المؤلفون: Negeem Z; Biotechnology and Life Sciences Department, Faculty of Postgraduate Studies for Advanced Sciences (PSAS), Beni-Suef University, Beni-Suef, Egypt., Abdel Moneim A; Molecular Physiology Division, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt., Mahmoud B; Department of Biochemistry, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt., Ahmed AE; Biotechnology and Life Sciences Department, Faculty of Postgraduate Studies for Advanced Sciences (PSAS), Beni-Suef University, Beni-Suef, Egypt., Abd El-Hameed AM; Department of Chemistry, Faculty of Science, Taibah University, Al-Madinah Al-Munawarah, Saudi Arabia., Eskandrani AA; Department of Chemistry, Faculty of Science, Taibah University, Al-Madinah Al-Munawarah, Saudi Arabia., Hasona NA; Department of Biochemistry, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt.
المصدر: Saudi journal of biological sciences [Saudi J Biol Sci] 2024 May; Vol. 31 (5), pp. 103975. Date of Electronic Publication: 2024 Mar 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Saudi Biological Society Country of Publication: Saudi Arabia NLM ID: 101543796 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1319-562X (Print) Linking ISSN: 22137106 NLM ISO Abbreviation: Saudi J Biol Sci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Riyadh : Saudi Biological Society : King Saud University, [2009]-
مستخلص: Aim: The primary factor causing chronic renal failure is diabetic nephropathy (DN) worldwide. However, the current biomarkers for DN have limited diagnostic utility. Thus, this work aimed to clarify the implications of microRNA-200a (miR-200a) and microRNA-132 (miR-132) and their correlation with NF-κB (nuclear factor- kappa beta), and, TNF-α (tumor necrosis factor -alpha) signaling to identify biomarkers able to distinguish late-stage from early- stage DN.
Methods: Fifty healthy controls, and 271 type 2 diabetic (T2D) patients (166 male plus 105 female) were enrolled. Participants were stratified into seven groups according to along with the estimated glomerular filtration rate (eGFR), glycated hemoglobin (HbA1c%), healthy controls, diabetes without DN (G1), diabetes with mild renal impairment (G2), and four DN grades (G3a, G3b, G4, and G5).
Results: Compared to healthy controls, the DN groups exhibited linear increases in serum miR-200a, TNF-α, NF-κB, matrix metalloproteinase (MMP-9) and interleukin-6 (IL-6) levels and reductions in miR-132 serum expression. Among the patients, NF-κB and TNF-α produced a negative correlation with miR-132, while, positive correlation has been discovered with miR-200-a. The operating characteristic of the receiver curve (ROC), proved that, miR-200a also miR-132 had good diagnostic performance in distinguishing early from advanced DN.
Conclusion: MiR-200a as well as miR-132 expression levels, and their correlations with NF-κB/TNF-alpha signaling, were able to differentiate between DN patients with lower eGFR, suggesting their utility as diagnostic and prognostic biomarkers.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2024 The Author(s).)
References: Front Cell Dev Biol. 2021 Jan 25;8:618536. (PMID: 33569382)
Biotherapy. 1991;3(2):127-33. (PMID: 2054253)
Int Urol Nephrol. 2022 Apr;54(4):937-947. (PMID: 34312814)
Chem Biol Interact. 2021 Oct 1;348:109625. (PMID: 34416245)
J Diabetes Metab Disord. 2020 Nov 24;19(2):1599-1607. (PMID: 33520856)
Front Physiol. 2021 May 05;12:649587. (PMID: 34025445)
Eur Rev Med Pharmacol Sci. 2020 Nov;24(22):11865-11870. (PMID: 33275257)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Medicine (Baltimore). 2020 Sep 18;99(38):e22278. (PMID: 32957381)
J Dermatol. 2016 Nov;43(11):1267-1272. (PMID: 27062420)
Ann Hematol. 1991 Jun;62(6):203-10. (PMID: 1854882)
Arch Biochem Biophys. 2020 Oct 15;692:108530. (PMID: 32768395)
Front Endocrinol (Lausanne). 2018 May 22;9:225. (PMID: 29910771)
Endokrynol Pol. 2018;69(3):269-275. (PMID: 29952417)
Diabetes. 2019 Dec;68(12):2287-2300. (PMID: 31506344)
Expert Rev Clin Immunol. 2022 Apr;18(4):377-389. (PMID: 35212585)
J Biol Chem. 2015 Oct 9;290(41):24793-805. (PMID: 26292219)
J Am Soc Nephrol. 2017 Oct;28(10):2985-2992. (PMID: 28663230)
PLoS One. 2014 Jun 17;9(6):e99633. (PMID: 24936866)
Diagn Pathol. 2019 Oct 25;14(1):119. (PMID: 31653266)
Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1715-1727. (PMID: 33239409)
J Endocrinol. 2020 Apr;245(1):129-140. (PMID: 32031966)
Biomed Res Int. 2016;2016:1627143. (PMID: 27631001)
Ann Intern Med. 2006 Aug 15;145(4):247-54. (PMID: 16908915)
Life (Basel). 2022 Aug 08;12(8):. (PMID: 36013381)
J Diabetes Res. 2020 Jun 19;2020:3960857. (PMID: 32656264)
J Cell Mol Med. 2021 Aug;25(16):7783-7795. (PMID: 34160889)
Lab Invest. 2018 Apr;98(4):427-438. (PMID: 29330473)
Biochemistry (Mosc). 2021 Feb;86(2):179-189. (PMID: 33832416)
Biomedicines. 2021 Feb 11;9(2):. (PMID: 33670423)
Diabetes Metab Syndr Obes. 2017 Jun 07;10:207-222. (PMID: 28652790)
Diabetes Obes Metab. 2020 Apr;22 Suppl 1:3-15. (PMID: 32267079)
Biomed Res Int. 2015;2015:465479. (PMID: 26106607)
Front Pharmacol. 2017 Oct 25;8:770. (PMID: 29118714)
Aging (Albany NY). 2020 Dec 27;13(3):4590-4604. (PMID: 33406505)
Front Genet. 2020 Aug 25;11:993. (PMID: 33193581)
Front Mol Biosci. 2021 Jul 26;8:707461. (PMID: 34381815)
Nat Rev Nephrol. 2020 May;16(5):269-288. (PMID: 32060481)
Cancer Cell Int. 2021 Aug 21;21(1):439. (PMID: 34419060)
EMBO J. 2018 Dec 14;37(24):. (PMID: 30467221)
Clin Exp Nephrol. 2015 Feb;19(1):1-5. (PMID: 25527479)
Mol Biol Rep. 2022 May;49(5):3803-3809. (PMID: 35277788)
PLoS One. 2020 Jul 29;15(7):e0236453. (PMID: 32726329)
Tumori. 2013 Jul-Aug;99(4):523-9. (PMID: 24326842)
Diabetologia. 1985 Jul;28(7):412-9. (PMID: 3899825)
Am J Physiol Renal Physiol. 2018 Jun 1;314(6):F1087-F1095. (PMID: 29357421)
Diabetologia. 2016 Jul;59(7):1558-1568. (PMID: 27115417)
فهرسة مساهمة: Keywords: Diabetic nephropathy; Matrix metalloproteinase-9; Nuclear factor kabba -beta; Tumor necrosis factor -alpha; microRNA-132; microRNA-200a
تواريخ الأحداث: Date Created: 20240328 Latest Revision: 20240329
رمز التحديث: 20240329
مُعرف محوري في PubMed: PMC10966293
DOI: 10.1016/j.sjbs.2024.103975
PMID: 38544953
قاعدة البيانات: MEDLINE
الوصف
تدمد:1319-562X
DOI:10.1016/j.sjbs.2024.103975